Clinical trial
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
Recruiting now · Not applicable · 1 countries · Registry ID NCT07703683
Recruiting nowNot applicableObservational
What this study is about
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionDiabetes, Obesity & Overweight, Cushing Syndrome, Metabolic Diseases, Endocrine Diseases, Sarcopenia, Sarcopenic Obesity
Full registry criteria
Inclusion Criteria: * Metabolic or endocrine disease Exclusion Criteria: * Known myopathy * Systemic steroid use (\> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome * Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol * History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor
Treatments and study arms
GLP-1 Receptor Agonists
Drug
Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
Primary outcomes
Prevalence of sarcopenia / sarcopenic obesityFrom February 2026 to december 2056
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Cliniques Universitaires Saint-Luc🇧🇪 Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Belgium
Laura Orioli, MD, PhDContact